Synopsis

Source of validity: Scientific
Rating (out of 5): 2

There is emerging scientific interest in the relationship between Akkermansia muciniphila and Parkinson’s Disease (PD), but evidence supporting its use as a treatment or supportive intervention for PD is limited and primarily preclinical. A. muciniphila is a mucin-degrading bacterium that is commonly found in the human gut. Recent research has identified alterations in the gut microbiota of individuals with PD, including increased abundance of A. muciniphila compared to healthy controls. However, it remains unclear whether these changes are a cause, consequence, or compensatory mechanism related to the disease process.

Some animal studies have suggested that A. muciniphila may improve aspects of gut barrier function and inflammation, which are thought to be relevant in the pathogenesis of PD due to the gut-brain axis. However, there are also studies indicating that higher levels of A. muciniphila may correlate with worsened constipation and motor symptoms in PD patients. There are currently no robust clinical trials demonstrating that supplementation with A. muciniphila improves PD symptoms or modifies disease progression in humans.

In summary, while there is scientific exploration of the role of A. muciniphila in PD, current evidence is preliminary and does not justify its use as a treatment. Its presence in PD studies is more a marker of microbiome alteration than a validated therapeutic target at this time.

More about Akkermansia muciniphila
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by Akkermansia muciniphila

Products containing Akkermansia muciniphila

Metagenics Akkermansia Co.™ Healthy Weight with Glucose Control
Metagenics UltraFlora Triplebiotic